Nexus of Pathophysiology and Therapeutics (NPT) is a peer-reviewed, open-access journal committed to advancing the mechanistic understanding of disease biology and translating these insights into therapeutic innovation.
The journal publishes high-quality research elucidating molecular, cellular, tissue, and systems-level mechanisms underlying disease processes and therapeutic responses. NPT emphasizes studies that provide causal and mechanistic insight, moving beyond descriptive observations toward explanatory and translational biology.
NPT serves as a premier platform for integrating experimental, computational, and clinical research, effectively bridging the continuum from fundamental discovery to real-world therapeutic application.
NPT publishes original research across the full spectrum of mechanistic and translational biomedical science, focusing on the following core domains:
Pharmacology & Therapeutic Mechanisms: Pharmacodynamics, pharmacokinetics, molecular mechanisms of drug action, therapeutic target validation, and the development of novel pharmacological or biological interventions.
Molecular & Cellular Pathophysiology: Molecular and cellular mechanisms underlying disease initiation and progression, including intracellular signaling pathways, gene regulation, cellular stress responses, and disease-associated metabolic or molecular alterations.
Clinical & Translational Mechanistic Studies: Mechanistic clinical investigations evaluating biological pathways, therapeutic target engagement, pharmacodynamic responses, biomarker dynamics, or mechanistic heterogeneity in patient populations. We highly welcome well-designed prospective and retrospective cohorts, patient-derived biobank analyses, and clinical registry studies, provided they are framed within a clear mechanistic or pathophysiological context.
Translational Pathophysiology & Experimental Medicine: Studies bridging basic biological discoveries with clinical relevance, including in vivo and in vitro experimental models, disease modeling, translational investigations, and preclinical target validation.
Therapeutic Innovation & Biomedical Engineering: Medical device development with mechanistic validation; surgical and interventional innovations with clear biological rationales; advanced drug delivery systems and formulation science; AI/ML tools with biological or pharmacological interpretability; and diagnostic prototypes bridging laboratory discovery to clinical application.
Immunopathology & Inflammatory Mechanisms: Immune-mediated disease mechanisms, inflammatory signaling cascades, immune dysregulation, and immune-targeted therapeutic strategies.
Systems Biology, Omics & Precision Medicine: High-throughput systems biology approaches, multi-omics analyses (genomics, transcriptomics, proteomics, metabolomics), biomarker discovery pipelines, and computational modeling with explicit therapeutic relevance.
While NPT considers high-quality mechanistic studies across all areas of biomedicine, it focuses primarily on:
Oncology (Tumor microenvironment, signaling, and resistance pathways)
Cardiovascular Diseases (Ischemic pathways, remodeling, and vascular biology)
Neuroscience & Neurodegeneration (Synaptic dysfunction, neuroinflammation, and proteinopathies)
Metabolic Disorders (Endocrine pathways, insulin resistance, and metabolic syndrome)
Immunopathology & Inflammatory Diseases (Autoimmunity and chronic inflammatory states)
Infectious Diseases (Host-pathogen interactions and antimicrobial mechanisms)
NPT prioritizes manuscripts that:
Establish causal biological mechanisms rather than purely associative findings.
Demonstrate exceptional methodological rigor, transparency, and reproducibility.
Integrate findings across multiple biological scales (from molecular interactions to clinical outcomes).
Provide clear, actionable translational or therapeutic relevance.
NPT recognizes the immense value of retrospective and observational clinical datasets in explaining real-world therapeutic outcomes and disease progression. Retrospective studies are welcome for evaluation, provided they move beyond simple descriptive charting or basic demographic profiling.
To be eligible for peer review, retrospective manuscripts must evaluate clinical outcomes, biomarkers, or therapeutic responses through a clear pathophysiological lens. This mechanistic evaluation can be achieved either:
Directly within the empirical data: By explicitly analyzing historical biomarker dynamics, tissue-level alterations, or biological parameters.
Within the scholarly framing: By integrating a robust, biologically grounded, and deeply analytical evaluation within the Introduction and Discussion sections to mechanistically explain the biological reasons, signaling pathways, and pathophysiological underpinnings behind the observed clinical outcomes or therapeutic responses.
To ensure comprehensive scientific discourse, NPT accepts the following manuscript categories:
Original Research Articles
Mechanistic & Translational Studies
Review Articles & Mechanistic Reviews
Short Communications & Brief Reports
Methodology & Experimental Frameworks
Commentaries & Editorials
Study Protocols
Nexus of Pathophysiology & Therapeutics is engineered for biomedical researchers who aim not merely to describe biological phenomena, but to explain them mechanistically and translate that profound understanding into future therapeutic advancement.
